Semax

Origin and Structure

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro — the first four residues correspond to a fragment of adrenocorticotropic hormone (ACTH 4-7), with a modified C-terminal Pro-Gly-Pro tail added to extend metabolic stability. It was developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences as part of a program to engineer short, CNS-active fragments of pituitary hormones that retained neurotropic activity but shed hormonal activity.

Semax has been registered as a medicine in Russia since 1996, where it is used in clinical practice for stroke recovery, cognitive impairment, and optic nerve disorders. Outside of Russia and a small number of neighboring countries, it has no approved indication and is treated as a research compound. Administration is typically intranasal — the peptide is small and charged enough to cross the nasal mucosa and reach the CNS via the olfactory pathway.

Mechanism of Action

Semax's principal mechanism appears to be modulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression. Multiple rodent studies have reported rapid (within hours) upregulation of BDNF mRNA in the hippocampus and prefrontal cortex following intranasal administration. Because BDNF plays a central role in synaptic plasticity, long-term potentiation, and neuronal survival, this effect is the most frequently cited explanation for Semax's reported cognitive and neuroprotective properties.

Semax has also been shown to modulate enkephalin and endorphin levels by inhibiting their enzymatic degradation, which may contribute to its mild anxiolytic and stress-buffering effects reported in animal models.

Clinical Evidence

Most of the human clinical literature on Semax is published in Russian-language journals, with a subset available in English translation. The evidence base is concentrated in three areas:

• Acute ischemic stroke. Several Russian multicenter trials have reported improved neurological recovery scores when Semax is administered early after ischemic stroke, used as an adjunct to standard care.
• Cognitive impairment. Smaller studies have examined Semax for age-related cognitive decline and post-concussion syndrome, with modest effect sizes reported on attention and working memory tasks.
• Optic nerve disorders. Semax is registered in Russia for optic nerve atrophy, with some trial data suggesting benefit on visual field and acuity measures.

The evidence base has two important caveats: much of the research originates from a small number of Russian research groups with limited independent replication, and methodology varies substantially across studies. Reviews in English-language journals have generally concluded that Semax shows signal but that larger, better-controlled international trials are needed.

Practical Considerations

Clinical and research protocols typically use intranasal administration at 250–1000 mcg per day, divided across two or three applications. The peptide is usually supplied as a 0.1% or 1% aqueous nasal spray. Onset of subjective effects — when reported — is within 10–30 minutes, consistent with rapid nasal-to-CNS transit.

Semax is sometimes used alongside Selank, another Russian-developed neuropeptide with complementary anxiolytic properties. The two are mechanistically distinct — Selank is derived from tuftsin and acts primarily on GABAergic signaling — but they are frequently discussed together in the nootropic-peptide context.

Safety and Regulatory Status

The side effect profile reported in Russian clinical use is mild — occasional nasal irritation, mild drowsiness or headache, and rare reports of paradoxical agitation. No significant cardiovascular, endocrine, or hepatic toxicity signals have emerged in decades of clinical use.

Semax is not approved by the FDA, EMA, or most other major regulators. It is available in Western markets only through research-chemical suppliers or by import from Russia, and peptide purity from gray-market sources can vary considerably. For those evaluating nootropic peptides more broadly, Semax occupies an unusual position: more real-world human exposure than almost any peptide in this library, but concentrated in a single jurisdiction, which leaves the international research community with a frustratingly incomplete picture.